Quantum dot-DNA microsphere aptamer biosensor with AI-assisted structural modeling for rapid detection of the lung cancer biomarker USE1.
[BACKGROUND] Lung cancer remains a leading cause of cancer-related mortality worldwide, highlighting the urgent need for rapid, accurate, and affordable diagnostic strategies.
- Sensitivity 93.3%
APA
Kim MJ, Yum K, et al. (2026). Quantum dot-DNA microsphere aptamer biosensor with AI-assisted structural modeling for rapid detection of the lung cancer biomarker USE1.. Journal of nanobiotechnology. https://doi.org/10.1186/s12951-026-04384-4
MLA
Kim MJ, et al.. "Quantum dot-DNA microsphere aptamer biosensor with AI-assisted structural modeling for rapid detection of the lung cancer biomarker USE1.." Journal of nanobiotechnology, 2026.
PMID
41981644
Abstract
[BACKGROUND] Lung cancer remains a leading cause of cancer-related mortality worldwide, highlighting the urgent need for rapid, accurate, and affordable diagnostic strategies. UBA6-specific E2 conjugating enzyme 1 (USE1) is overexpressed in lung cancer and contributes to tumorigenesis, yet no clinically applicable method exists for its detection.
[RESULTS] We developed an AI-assisted aptamer biosensing platform for antibody-free detection of USE1. High-affinity candidates (Aptamer 1e) were identified through systematic SELEX and rational truncation, and AlphaFold3-based modeling was subsequently applied post hoc to provide a structural hypothesis for the observed binding. For signal amplification and visualization, we engineered a nanostructured detection system composed of rolling-circle-amplified DNA microspheres (DNAMS) conjugated with streptavidin-quantum dots (STA-QDs). The DNAMS-STA-QD biosensor enabled strong fluorescence signals in USE1-positive cancer cells and produced a clear visual distinction between tumor and matched normal lung tissues. In 30 paired tissue samples, the biosensor achieved AUC = 0.961, with 86.7% sensitivity and 93.3% specificity for detecting lung cancer. The assay requires no antibodies, enzymatic amplification, or specialized instrumentation, and offers a rapid, low-cost workflow.
[CONCLUSIONS] This study presents a clinically oriented nanobiosensing platform that integrates AI-assisted aptamer structural modeling with quantum dot-enhanced DNA nanostructures for sensitive detection of USE1. The approach offers a robust, antibody-free method for lung cancer diagnosis and demonstrates the potential of combining deep learning with nanobiotechnology to accelerate biomarker detection tool development.
[RESULTS] We developed an AI-assisted aptamer biosensing platform for antibody-free detection of USE1. High-affinity candidates (Aptamer 1e) were identified through systematic SELEX and rational truncation, and AlphaFold3-based modeling was subsequently applied post hoc to provide a structural hypothesis for the observed binding. For signal amplification and visualization, we engineered a nanostructured detection system composed of rolling-circle-amplified DNA microspheres (DNAMS) conjugated with streptavidin-quantum dots (STA-QDs). The DNAMS-STA-QD biosensor enabled strong fluorescence signals in USE1-positive cancer cells and produced a clear visual distinction between tumor and matched normal lung tissues. In 30 paired tissue samples, the biosensor achieved AUC = 0.961, with 86.7% sensitivity and 93.3% specificity for detecting lung cancer. The assay requires no antibodies, enzymatic amplification, or specialized instrumentation, and offers a rapid, low-cost workflow.
[CONCLUSIONS] This study presents a clinically oriented nanobiosensing platform that integrates AI-assisted aptamer structural modeling with quantum dot-enhanced DNA nanostructures for sensitive detection of USE1. The approach offers a robust, antibody-free method for lung cancer diagnosis and demonstrates the potential of combining deep learning with nanobiotechnology to accelerate biomarker detection tool development.
같은 제1저자의 인용 많은 논문 (5)
- Ex vivo magnetic resonance imaging using hyaluronic acid fillers: Differences between monophasic and biphasic fillers.
- Clinical implications of plasma EGFR T790M and ctDNA shedding across metastatic sites in plasma- or tissue-confirmed EGFR-mutant non-small cell lung cancer treated with lazertinib: a prospective multicenter cohort study.
- Value of TERT Promoter Mutations for Early Outcomes in Papillary Thyroid Cancer.
- Controversies in management of Helicobacter pylori infection from a U.S. perspective: population screening and treatment.
- A national survey of physicians regarding active surveillance for low-risk thyroid cancer in Korea.